FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid

Hoth Therapeutics regains Nasdaq compliance

TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement

Merry Life launches TML-6 global Phase II trial for Alzheimer's Disease

Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis

UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025

Azurity Pharmaceuticals' XIFYRM (meloxicam injection) approved by US FDA for moderate-to-severe pain management in adults

Eluminex Biosciences announces EB-105 Phase 1b single ascending dose study results in patients with diabetic macular edema

Vivoryon Therapeutics presents positive meta-analysis data for varoglutamstat

Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease

Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal

Genentech reports sustained two-year benefits from fenebrutinib in relapsing multiple sclerosis

RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis

Celltrion announces FDA interchangeability designation for all YUFLYMA's approved dosage forms and strengths

TME Pharma announces extension of financial visibility to May 2026